|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Here, we focused on Akt kinase-interacting protein1 (Aki1), a scaffold protein of PI3K (phosphoinositide 3-kinase)/PDK1 (3-phosphoinositide-dependent protein kinase)/Akt that determines receptor signal selectivity for non-mutated EGFR, and assessed its role in EGFR mutant lung cancer with or without gatekeeper T790M mutation.
|
23045273 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genetic variants in PI3K/AKT pathway are associated with severe radiation pneumonitis in lung cancer patients treated with radiation therapy.
|
26645682 |
2016 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutations have been associated with poor prognosis in patients with colorectal or lung cancer.
|
23532889 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Activation to a large extent of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway and mutations in the p53 gene are involved in lung cancer therapeutic resistance.
|
20811722 |
2010 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Aberrant activation of PI3K/AKT signalling represents one of the most common molecular alterations in lung cancer, though the relative contribution of the single components of the cascade to the NSCLC development is still poorly defined.
|
22363436 |
2012 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer.
|
24453288 |
2014 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We also evaluated epidermal growth factor receptor (EGFR) and PIK3CA mutations of captured CTC in a study of 4 lung cancer and 4 breast cancer patients.
|
26708016 |
2016 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
EGFR and HER2 mutations and ALK rearrangement are known to be related to lung cancer in never-smokers, while KRAS, BRAF and PIK3CA mutations are typically observed among smokers.
|
25745045 |
2015 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
|
27121230 |
2016 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We developed a highly sensitive LUNG CANCER (LC)-biochip approach for the detection of the most common EGFR, KRAS, PIK3CA, and BRAF gene mutations.
|
25153497 |
2015 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
To investigate the prevalence of phosphatidylinositol 3-kinase (PIK3CA) gene amplification in lung cancer, and to explore its prognostic value.
|
23335533 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Identification of uncommon PIK3CA mutations in lung cancer by using pyrosequencing.
|
23370426 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Lung cancer TCGA data validated these findings and unveiled overlap of FGFR1 mRNA positivity with KRAS and PIK3CA mutations.
|
24771645 |
2014 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, PIK3CA mutated lung cancer frequently develops in patients with prior malignancies.
|
25473901 |
2015 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
However, the clinico-pathological background for PIK3CA gene mutations has not yet been investigated in lung cancer.
|
16930767 |
2006 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
|
24743704 |
2014 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA mutation and amplification in human lung cancer.
|
17803655 |
2007 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Common molecular drivers of lung cancer are mutations in receptor tyrosine kinases (RTKs) leading to activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pro-growth, pro-survival signaling pathways.
|
25524703 |
2015 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Using the DNA extracted from formalin-fixed paraffin-embedded tumor samples, a MassArray-based Lung Cancer Mutations Screening Panel was performed to test for 179 individual mutations in 10 genes, including EGFR, KRAS, BRAF, ERBB2, JAK2, AKT1, AKT2, KIT, MET and PIK3CA, which have been implicated in lung carcinogenesis and/or considered as potential therapeutic targets.
|
23449277 |
2013 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, we report that the shRNA-mediated knockdown of RhoGDI2 induces the invasion and migration of lung cancer due to cross-talk with the PI3K/Akt pathway and MMP-9.
|
25266803 |
2015 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We further observed that oncogenic cooperation between KRAS(G12D) and PIK3CA(H1047R) was accompanied by PI3Kα-mediated regulation of c-MYC, GSK3β, p27(KIP1), survivin, and components of the RB pathway, resulting in accelerated cell division of human or mouse lung cancer-derived cell lines.
|
26567140 |
2015 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Data were reviewed for patients with advanced lung adenocarcinomas enrolled in the Lung Cancer Mutation Consortium whose tumors underwent testing for mutations in epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), human epidermal growth factor receptor 2 (HER2), AKT1, BRAF, dual-specificity mitogen-activated protein kinase kinase 1 (MEK1), neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS), and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit α (PIK3CA); for anaplastic lymphoma kinase (ALK) translocations; and for MET amplification.
|
25273224 |
2015 |
|
Carcinoma of lung
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
PIK3CA gene encoding a catalytic subunit of the phosphatidylinositol-3-kinase (PI3K) is mutated and/or amplified in various neoplasia, including lung cancer.
|
24533074 |
2014 |
|
Carcinoma of lung
|
0.500 |
Biomarker
|
disease |
BEFREE |
This study suggested that the PTEN/PI3K/AKT signaling pathway plays an important role in thrombin/PAR1-mediated lung cancer cell growth and migration.
|
25861627 |
2015 |